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   ABSTRACT 
 
Background: Thalassemia is a blood disease 
characterized by the most frequently found auto-
somal recessive hereditary hemolytic anemia. It 
requires repeated blood transfusions for life. 
Routine blood transfusion can cause complica-
tions in the form of accumulation of ferritin in 
the tissue. Iron chelation therapy is considered 
effective for treating body iron deposits. How-
ever, iron chelation therapy has the side effect of 
decreasing levels of other important minerals 
such as zinc (Zn). This study aimed to examine 
plasma zinc difference in children with Thalasse-
mia β major received deferiprone or deferasirox 
zinc. 
Subjects and Method: This was a cross sec-
tional study conducted at Dr. Moewardi Hospital, 
Surakarta, from February to April 2017. A sample 
of 40 children with thalassemia β major aged 3 to 
18 years who received deferiprone iron chelation 
and deferasirox at least 6 months was selected by 
consecutive sampling. The dependent variable 
was serum zinc levels. The independent variables 
were iron deferiprone and deferasirox. Plasma 
zinc levels were measured by atomic absorption 
spectroscope. The data were analyzed by t test. 
Results: Zinc levels in patients with deferiprone 
therapy (Mean= 54.50; SD= 11.02) were lower 
than deferasirox therapy (Mean= 60.95; SD= 
20.71), but statistically not significant (p= 0.229). 
Conclusion:Zinc levels in patients with deferi-
prone therapy are lower than deferasirox therapy, 
but not statistically significant. 
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BACKGROUND 
Thalassemia is a blood disease characterized 
by autosomal recessive hereditary hemolytic 
anemia which is most commonly found (Per-
mono, 2006; David W, 2004). Thalassemia 
sufferers require lifelong repeated blood 
transfusions due to hemolytic processes that 
occur continuously (Permono, 2006; Capel-
lini, 2008, Lanzkowsky P, 2011). Routine 
blood transfusion can cause accumulation of 
iron levels in tissues and organs and can 
affect the function of these organs, including 
the heart, liver, endocrine glands, bones, 
lungs and central nervous system (Borgna-
Pignatti, 2004; Capellini, 2008; Khan, 2007). 
To overcome the body's iron deposits, 
iron chelation therapy is used. The therapy is 
considered effective in reducing ferritin 
levels, but has another effect, which is to dec-
rease other important minerals in the body, 
namely zinc (Satwani, 2005). Existing studies 
have different results regarding the effect of 
giving a certain iron chelation to plasma zinc 
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levels, other than that there is no consensus 
on the examination of zinc levels in patients 
with thalassemia major, making researchers 
interested in doing about differences in 
serum zinc levels in patients who get deferi-
prone iron chelation with deferasirox in 
thalassemia major β patients. 
 
SUBJECTS AND METHOD 
1. Study Design 
This was an analytic observational study with 
a cross sectional design. 
2. Population dan Sample 
Subjects in this study were pediatric thalasse-
mia β major patients aged 3-18 years. The 
target population is pediatric patients with 
thalassemia β major. Affordable population is 
pediatric thalassemia major β patients who 
are in the Hospital Dr. Moewardi Surakarta 
between February 2017 to April 2017. 
Sampling as a research subject was conduc-
ted by consecutive sampling method. Each 
pediatric thalassemia β major patient who 
met the study criteria was included in the 
study. The inclusion criteria were pediatric 
thalassemia patients aged 3-18 years who 
were treated between February 2017 and 
April 2017 with a length of deferiprone and 
deferasirox iron chelation for a minimum of 6 
months, and parents or guardians were will-
ing to sign the research informed consent. 
Exclusion criteria were patients with poor 
nutrition, diarrhea, and patients who took 
zinc preparations within 14 days before sam-
pling. 
3. Study Variables 
The independent variables in this study were 
flat iron deferiprone and deferasirox. The 
dependent variable of this study is plasma 
zinc levels. The confounding variables of this 
study were adherence to taking iron chelation 
medication, inadequate nutrition intake, 




4. Operational Definition of Variables 
Flatfoot iron was divided into 2: (1) defera-
sirox; (2) deferiprone, which is consumed by 
patients with thalassemia β major for at least 
1 year at the time of the study, with a dose of 
75-100 mg/ kg of deferiprone and a dose of 
20-30 mg/ kg of deferiprox. 
Plasma zinc levels were measured using 
an atomic absorption spectroscope (AAS) by 
taking patients' vein blood in the morning as 
much as 4 ml, were carried out in clinical 
laboratories, in units of grams/ dl. The mea-
surement scale is continuous and converted 
to a dichotomy, code 0= <70 g/ dl and nor-
mal= ≥70 g/ dl. 
Age was determined by the year value calcu-
lated at the time of data collection. The mea-
surement scale is continuous. 
Gender was divided into male and female. 
The measurement scale is categorical. 
Nutritional status was measured using a 
left upper arm circumference (MUAC) mea-
surement. The circumference of the upper 
arm is measured at the midpoint of the upper 
arm between the mid-acromion of the sca-
pula and the olecranon when the hand is 
flexed at a 900 angle. The measuring instru-
ment is the medline tape, the unit is in cm, 
the scale is ordinal, divided into three classes, 
namely good nutrition, poor nutrition, and 
poor nutrition. 
5. Data Analysis 
Characteristics of the sample are described in 
n and %. Differences in zinc levels in the 
deferiprone and deferasirox iron chelation 
group were analyzed using independent t 
test. 
6. Research Ethic 
This study was approved by the Board of 
Health Research Ethics Commission Dr. 
Moewardi Hospital/ Sebelas Maret Univer-
sity Faculty of Medicine Number: 851/X/ 
HREC / 2017. 
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RESULTS 
A. Sample Characteristics  
Sample characteristics  data were described 
in Table 1. 
B. Univariate analysis 
This study was carried out on 40 pediatric 
Thalassemia β major patients where 20 
patients were given iron deferasirox chelation 
therapy and 20 other patients were treated 
with iron deferiprone chelation. Charac-
teristic data are in the form of categorical 
data where the gender is tested differently 
with Chi Square because nominal categorical 
data while the number of transfusions and 
MoryskyAdehernce Scale the Mann Whitney 
test is done differently because the data with 
ordinal scale. 
Tabel 1. Sample of Characteristics 
Characteristics 
Flatfoot iron 
p Deferasirox Deferiprone 
n % N % 
Gender      
Male 12  60.0% 6 30.0% 0.057 
Female 8 40.0% 14  70.0%  
Amount of Transfusion      
1 bags 8 40.0% 4 20.0% 0.163 
2 bags 11 55.0% 14  70.0%  
3 bags    1 5.0% 2 10.0%  
Morysky Adeherence Scale     0.009 
0    1 5.0% 0 0%  
1    5 25.0% 0 0%  
2 14 70.0% 20 100.0%  
 
C. The result of bivariate analysis  
Table 2 shows that the level of GDS in pati-
ents on deferasirox therapy (Mean= 112.90; 
SD = 34.50), higher than deferiprone therapy  
(Mean= 85.25; SD = 30.26), and and statis-
tically significant (p= 0.007). SGOT levels in 
patients on deferasirox therapy (Mean= 
100.50; SD= 68.37) were higher than deferi-
prone therapy (Mean= 39.80; SD= 10.55), 
and statistically significant (p= 0.001). SGPT 
levels in patients on deferasirox therapy 
(Mean= 60.50; SD= 52.13) were higher than 
deferiprone therapy (Mean= 30.95; SD= 
20.13), and statistically significant (p= 
0.003). Ferritin levels in patients with defe-
rasirox therapy (Mean= 4,105.01; SD= 
1,394.70) were higher than deferiprone 
therapy (Mean= 4,080.19; SD= 2,004.34), 
but not statistically significant (p= 0.964). 




p Deferasirox Deferiprone 
Mean SD Mean SD 
GDS 112.90 34.50 85.25 30.26 0.007 
SGOT 100.50 68.37 39.80 10.55 0.001 
SGPT 60.50 52.13 30.95 20.13 0.003 
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Table 3. Differences in zinc levels by type of Deferasirox iron chelation therapy with 
Deferiprone therapy 
Flatfoot Iron Mean SD p 
Deferasirox 54.50 60.95 0.229 
Deferiprone 11.02 20.71  
Table 3 shows that zinc levels in pati-
ents on deferasirox therapy (Mean= 54.50; 
SD= 11.02) are lower than deferiprone thera-
py (Mean= 60.95; SD= 20.71), but statisti-
cally not significant (p= 0.229). 
Table 4 shows that there were almost 
no differences in levels of Defasirox or 
Deferiprone iron chelation based on the 
amount of blood transfusion. 
 
Table 4. Differences in Zinc Levels Based on Iron Flatfoot and Blood Transfusion 
Flatfoot And Transfusion n Mean SD    p 
Deferasirox-1 bag 8 56.13 13.86 0.722 
Deferasirox-2bags 11 53.00 9.51  
Deferasirox-3bags 1 58.00 <0.01  
Deferasirox-1 bag 4 65.25 15.35  
Deferiprone-2bags 14 61.29 23.36  
Deferiprone-3bags 2 50.00 5.66  
 
Table 5. Post Hoc Test 
Flatfoot And Transfusion Mean (95% CI)  p 
Deferasirox-1 bag Deferasirox-2 bags  3.13 (-8.15 - 14.40)        0.869 
Deferasirox-1 bag Deferasirox-3 bags  -1.88 (-36.64 - 32.89)        0.699 
Deferasirox-1 bag Deferiprone-1 bag -9.13 (-28.67 - 10.42)        0.349 
Deferasirox-1 bag Deferiprone-2 bags  -5.16 (-24.15 - 13.83)        0.608 
Deferasirox-1 bag Deferiprone-3 bags 6.13 (-17.79- 30.04)        0.794 
Deferasirox-2 bags Deferasirox-3 bags  -5.00 (-27.13 - 17.13)        0.244 
Deferasirox-2 bags Deferiprone-1 bag -12.25 (-26.29 - 1.79)        0.102 
Deferasirox-2 bags Deferiprone-2 bags  -8.29 (-23.83 - 7.26)        0.459 
Deferasirox-2 bags Deferiprone-3 bags 3.00 (-12.61 - 18.61)        0.843 
Deferasirox-3 bags Deferiprone-1 bag -7.25 (-61.86-47.36)        0.480 
Deferasirox-3 bags Deferiprone-2 bags -3.29 (-55.53 - 48.96)        0.643 
Deferasirox-3 bags Deferiprone-3 bags 8.00 (-80.03 - 96.03)         0.221 
Deferiprone-1 bag Deferiprone-2 bags 3.96 (-22.58-30.51)         0.671 
Deferiprone-1 bag Deferiprone-3 bags 15.25 (-17.43-47.93)         0.165 
Deferiprone-2 bags Deferiprone-3 bags 11.29 (-25.30 - 47.87)         0.577 
 
Table 6. Differences in zinc levels based on nutritional status 
Nutritional Status  Mean SD p 
Poor 54.29 16.59 0.180 
Good 60.26 16.68  
 
Table 6 shows zinc levels in patients with 
good nutritional status (Mean= 60.26; SD= 
16.68) higher than poor nutritional status 
(Mean= 54.29; SD= 16.59) but statistically 
not significant (p= 0.180). 
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DISCUSSION 
1. Sample characteristic in children 
with thalassemia β Major 
Characteristic data showed that there were 
no significant differences (p> 0.05) in sex 
and number of blood transfusions in the 
Deferasirox and Deferiprone iron chelers. 
This shows that the distribution of samples 
was evenly distributed across all sex groups 
and the amount of blood transfusion. All 
Deferiprone Iron Flatfoot respondents and 
most (70%) Deferasirox Flatfoot respondents 
have been undergoing treatment routinely 
based on the Morysky Adherence Scale score. 
However, there are significant differences 
between the two groups, so this is thought to 
be able to influence the results of the next 
follow-up examination. According to an 
article, non-compliance with thalassemia 
patients in implementing chelation therapy 
programs can be caused by psychological dis-
orders in patients, relatives with similar 
diseases, low family economy, lack of pa-
rental supervision, and reduced frequency of 
blood transfusions (Al-Kloub et al, 2014). 
Another article also agreed to explain that 
this non-compliance is caused by the 
patient's psychological condition, which is 
coupled with the patient's behavioral factors, 
such as living alone and difficult access to 
treatment (Vosper et al, 2018). 
2. The laboratory tests in children with 
thalassemia β Major 
Laboratory tests show that individuals tre-
ated with Deferasirox will have a significantly 
higher GDS, SGOT, and SGPT than indi-
viduals with Deferiprone therapy. Based on 
several articles, the increase in SGOT and 
SGPT is related to liver damage due to iron 
overload due to blood transfusion, and is not 
related to administration of iron chelation 
therapy (Jensen, 2002; Hagag et al., 2015). 
This difference shows that administration of 
Deferiprone has a therapeutic effect on liver 
damage due to iron overload better than 
Deferasirox. On the other hand, normal and 
relatively low mean GDS values in respon-
dents after iron chelation therapy were also 
found in several other studies (Chuansumrit 
et al., 2016; Gomber et al., 2017).  
According to both studies, the adminis-
tration of iron chelation will reduce the iron 
build up in the pancreas, thus improving the 
workings of pancreatic beta cells. In addition, 
Chuansumrit et al also suspected that insulin 
sensitivity would improve with administra-
tion of iron chelation in beta-type thalasse-
mia patients. From these results, it appears 
that Deferiprone has a therapeutic effect on 
pancreatic damage due to iron overlaod 
better than Deferasirox. The absence of a sig-
nificant difference between Deferiprone and 
Deferasirox against serum ferritin shows that 
both iron sailors have an equally strong effect 
in regulating serum ferritin levels. 
3. The results of examination of zinc in 
children with thalassemia β Major 
The results of examination of zinc levels in 
patients did not show significantly different 
results in administration of Deferasirox-
chelets and Deferipronechelers. This is in 
accordance with some previous studies (Lac-
howicz et al, 2015; Zekavat et al, 2018).  
Zekavat et al. (2018), shows that there 
is no significant difference between varia-
tions of the type of iron chelation drug given 
to patients against zinc levels in patients. The 
same study also mentioned that the group 
that took iron chelation therapy had lower 
serum zinc levels than those who were not 
treated with iron chelation. The adminis-
tration of iron chelation agents is thought to 
interfere with homeostasis from the equili-
brium of zinc (II) ion bonds, thereby causing 
a decrease in serum zinc levels (Lachowicz et 
al., 2015). Based on these results, Deferasirox 
flatfoot and Deferiprone flatfoot have the 
same strong effect in reducing serum zinc 
levels. 
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Zinc levels did not differ significantly 
with each transfusion bag and iron chelation. 
A study states that the administration of 
blood transfusion can significantly increase 
serum zinc levels (Kizilgun et al., 2016). This 
is thought to be caused by the effect of Defe-
rasirox and Deferiprone iron chelating agents 
which are equally strong in reducing zinc 
levels in patients, so the differences between 
groups become insignificant (Zekavat et al, 
2018). However, it is suspected there are 
other reasons that cause this insignificant 
difference. First, the distribution of respon-
dents was uneven in several groups. Each 
group does not consist of the same number of 
respondents, so it will affect the average of 
each group. Secondly, the presence of zinc 
intake in the respondents' diet is thought to 
have influenced the results of serum zinc 
levels. Respondents with lower zinc con-
sumption will have lower serum zinc levels, 
and are more at risk of developing growth 
disorders during the course of thalassemia 
(Fung, 2016). 
4. The nutritional status in children 
with thalassemia β Major 
The results showed that nutritional status 
was not significantly related to serum zinc 
levels in patients. However, based on several 
existing studies, there is a relationship 
between nutritional status and serum zinc 
levels (Fung, 2016; Kulathinal et al., 2016). 
This is likely because the nutritional status of 
the patient is measured by measuring the 
upper arm circumference. A study states that 
the measurement of nutritional status by the 
waist circumference method shows a signi-
ficant relationship to serum zinc levels in 
respondents (Kulathinal et al, 2016). 
Limitation of this study is the absence 
of respondents who act as controls in the 
study. The control meant were respondents 
with beta thalassemia who did not undergo 
blood transfusion and iron chelation therapy, 
or who did blood transfusion but were not 
treated with iron chelation. A study with pre 
and post test evaluation methods is also 
needed to be able to evaluate differences in 
laboratory value parameters such as zinc, 
ferritin, GDS, SGOT, SGPT before and after 
iron chelation is given. 
Based on the results, it can be conclu-
ded that there is an influence between the ad-
ministration of iron chelation on zinc, GDS, 
SGOT, SGPT, and ferritin levels. There are 
also significant differences between Ferro-
siprox and Deferasirox chelation on serum 
levels of GDS, SGOT, and SGPT, but not on 
zinc and ferritin levels. In addition, the 
patient's nutritional status is not related to 
zinc levels in the patient. 
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